Overall survival of recurrent/metastatic head & neck squamous cell carcinoma patients progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy: results of SAKK 11/16, a phase IIa trial

Abstract Background Over the past two decades, most cancer vaccines have failed to be developed clinically. The lack of efficient priming with specific tumor antigens and/or weak adjuvants may explain this poor success rate. MVX-ONCO-1, a personalized cell-based vaccine, combines inactivated autolog...

Description complète

Détails bibliographiques

Auteurs principaux:	Eugenio Fernandez, Rémi Vernet, Muriel Urwyler, Olivier Von Rohr, Emily Charrier, Marie-Claude Belkouch, Valentin Saingier, Fabien Courtout, Claudio DeVito, Virginie Ancrenaz, Nicolas Dulguerov, Wolfram Karenovics, Julien Grogg, Jessica Renaux, Katrin Gobat, Gisela Müller, Tomas Brezina, Tamara Rordorf, Markus Joerger, Olivier Michielin, Jean Villard, Nicolas Mach
Format:	Artigo
Langue:	Inglês
Publié:	BMC 2025-08-01
Collection:	Experimental Hematology & Oncology
Sujets:	Immunotherapy Cell encapsulation device Granulocyte–macrophage colony stimulating factor Autologous irradiated tumor cells Advanced solid tumors
Accès en ligne:	https://doi.org/10.1186/s40164-025-00703-x
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!